What's Happening?
The FDA has agreed to reconsider its previous rejection of Ebvallo, a T-cell therapy developed by Pierre Fabre Pharmaceuticals and Atara Biotherapeutics for treating relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative
disease (EBV+PTLD). Initially rejected in January 2026 due to concerns over the adequacy of a single-arm trial, the FDA now acknowledges that such a study, with appropriate historical controls, could support an application for approval. The companies plan to resubmit the therapy with additional patient data and extended follow-up. Ebvallo has already been approved in Europe for this indication.
Why It's Important?
The reconsideration by the FDA is significant for patients with EBV+PTLD, a rare and aggressive cancer with limited treatment options. Approval of Ebvallo in the U.S. could provide a much-needed therapy for this ultra-rare condition, potentially improving survival rates for affected patients. The decision also highlights the FDA's evolving stance on the use of single-arm trials for rare diseases, which could influence future regulatory strategies for similar therapies. The outcome of this reconsideration could set a precedent for other companies seeking approval for treatments based on non-traditional trial designs.
What's Next?
Pierre Fabre and Atara Biotherapeutics will work on finalizing their resubmission plan with the FDA, aiming to address the agency's previous concerns. The companies will focus on gathering additional data to strengthen their application. The FDA's decision on Ebvallo could impact other pending applications, such as uniQure's Huntington's disease gene therapy, which also relies on single-arm trial data. The industry will be closely watching the FDA's actions, as they may signal broader regulatory shifts in the approval process for rare disease treatments.
